Skip to main content
SpringerLink
Log in

Tumor necrosis factor: An update on basic research and clinical applications

  • Review
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Tumor necrosis factor is one of the recently cloned cytokines with pleiotropic effects on normal and malignant cells. Our knowledge about the scope of cells producing or responding to this cytokine has enormously expanded. In critically ill patients with acute hepatic failure, acute graft-versus-host disease, or septic shock, circulating tumor necrosis factor can be measured and useful prognostic correlations do exist. Despite promising in vitro results, early clinical trials with tumor necrosis factor for the treatment of cancer have failed thus far to reveal major antineoplastic activity in cancer patients. However, more clinical trials are necessary, since different routes of administration and combinations with other cytokines may lead to favorable results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

TNF:

tumor necrosis factor

References

  1. Bakouche O, Ichinose Y, Heicappell R, Fidler I, Lachman LB (1988) Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor. J Immunol 140:1142–1147

    Google Scholar 

  2. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W (1987) Evidence for tumour necrosis factor/cachectin production in cancer. Lancet ii:1229–1232

    Google Scholar 

  3. Bartsch HH, Pfizenmaier K, Schröder M, Nagel GA (1989) Systemische versus lokale Therapie mit rekombinantem Tumor-Nekrose-Faktor-alpha (r-TNF-alpha) bei Patienten mit fortgeschrittenen Tumoren. Onkologie 12:136–141

    Google Scholar 

  4. Bartsch HH, Pfizenmaier K, Schröder M, Nagel GA (1989) Intralesional application of recombinant human tumor necrosis factorα induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 25:287–291

    Google Scholar 

  5. Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, Krönke M (1989) Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 86:5064–5068

    Google Scholar 

  6. Berger M, Wetzler EM, Wallis RS (1988) Tumor necrosis factor is the major monocyte product that increases complement receptor expression on mature human neutrophils. Blood 71:151–158

    Google Scholar 

  7. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379–385

    Google Scholar 

  8. Bringman TS, Aggarwal BB (1987) Monoclonal antibodies to human tumor necrosis factorsα andβ: application for affinity purification, immunoassays, and as structural probes. Hybridoma 6:489–507

    Google Scholar 

  9. Broudy VC, Harlan JM, Adamson JW (1987) Disparate effects of tumor necrosis factor α/β/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. J Immunol 138:4298–4302

    Google Scholar 

  10. Chen MJ, Holskin B, Strickler J, Gorniak J, Clark MA, Johnson PJ, Mitcho M, Shalloway D (1987) Induction by E1A oncogene expression of cellular susceptibility of lysis by TNF. Nature 330:581–583

    Google Scholar 

  11. Chensue SW, Remick DG, Shmyr-Forsch C, Beals TF, Kunkel SL (1988) Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. Am J Pathol 133:564–572

    Google Scholar 

  12. Cohen J (1988) Cytokines as mediators of graft-versus-host disease. Bone Marrow Transpl 3:193–197

    Google Scholar 

  13. Collart MA, Belin D, Vassali JD, de Kossodo S, Vassali P (1986)γ Interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 164:2113–2118

    Google Scholar 

  14. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK (1988) Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet ii:969–971

    Google Scholar 

  15. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK (1988) A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62:2467–2471

    Google Scholar 

  16. Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G (1987) Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 165:1581–1594

    Google Scholar 

  17. Darlington GJ, Wilson DR, Lachman LB (1986) Monocyteconditioned medium, interleukin 1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 103:787–793

    Google Scholar 

  18. Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489–494

    Google Scholar 

  19. Diehl V, Pfreundschuh M, Steinmetz HT, Tüschen R, Schenk V, Schaadt M (1989) Phase-I-study of intratumoral application of recombinant tumor necrosis factor. Mol Biother (Suppl) Abstr. # 71

  20. Dubois CM, Bissonnette E, Rola-Pleszczynski M (1989) Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4. Am Rev Resp Dis 139:1257–1264

    Google Scholar 

  21. Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC, Morton DL (1989) Genetic analysis of the human tumor necrosis factorα/cachectin promoter region in a macrophage cell line. J Exp Med 170:321–326

    Google Scholar 

  22. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JWM, Cannon JG, Rogers TS, Klempner MS, Weber PC, Schaefer EJ, Wolff SM, Dinarello CA (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271

    Google Scholar 

  23. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU (1988) A phase I clinical trial of intravenouslyadministered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 6:1328–1334

    Google Scholar 

  24. Garrett IR, Durie BGM, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR (1987) Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317:526–532

    Google Scholar 

  25. Ghiara P, Boraschi D, Nencioni L, Ghezzi P, Tagliabue A (1987) Enhancement of in vivo immune response by tumor necrosis factor. J Immunol 139:3676–3679

    Google Scholar 

  26. Girardin E, Grau GE, Dayer J-M, Roux-Lombard P, Study Group J5, Lambert P-H (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397–400

    Google Scholar 

  27. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WSM (1988) A 14,700 WM protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53:341–346

    Google Scholar 

  28. Grau GG, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lambert P-H (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 320:1586–1591

    Google Scholar 

  29. Hajjar KA, Hajjar DP, Silverstein RL, Nachman RL (1987) Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med 166:235–245

    Google Scholar 

  30. Havell EA, Fiers W, North RJ (1988) The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically mediated, and limited by severe toxicity. J Exp Med 167:1067–1085

    Google Scholar 

  31. Holler E, Kolb HJ, Möller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermüller J, Wilmanns W (1989) Increased serum levels of tumor-necrosis factor alpha (TNF alpha) precede major complicaitons of bone marrow transplantation. Blood 75:1011–1016

    Google Scholar 

  32. Imamura K, Spriggs D, Kufe D (1987) Expression of tumor necrosis factor receptor on human monocytes and internalization of receptor bound ligand. J Immunol 139:2989–2992

    Google Scholar 

  33. Ito Y, Kawamura K, Miura T, Ueda K, Onodera H, Takahashi H, Horikoshi T, Sugiyama S, Takahashi M (1989) Merkel cell carcinoma. A successful treatment with tumor necrosis factor. Arch Dermatol 125:1093–1095

    Google Scholar 

  34. Jacob CO, McDevitt HO (1988) Tumour necrosis factor-α in murine autoimmune “lupus” nephritis. Nature 331:356–358

    Google Scholar 

  35. Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF (1989) Phase I clinical trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7:298–303

    Google Scholar 

  36. Johnson CS, Chang MJ, Furmanski P (1988) In vivo hematopoietic effects of tumor necrosis factor-α in normal and erythroleukemic mice: characterization and therapeutic applications. Blood 72:1875–1883

    Google Scholar 

  37. Jones EY, Stuart DI, Walker NPC (1989) Structure of tumour necrosis factor. Nature 338:225–228

    Google Scholar 

  38. Kehrl JH, Miller A, Fauci AS (1987) Effect of tumor necrosis factor-α on mitogen-activated human B cells. J Exp Med 166:786–791

    Google Scholar 

  39. Kist A, Ho AD, Räth U, Wiedenmann B, Bauer A, Schlick E, Kirchner H, Männel DN (1988) Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood 72:344–348

    Google Scholar 

  40. Kloke O, Moritz T, Pladeck E, Nagel-Hiemke, Niederle N (1989) Combined administration of IFNα and TNFα in patients with CML and secondary resistance to IFN. Mol Biother (Suppl) Abstr. #104

  41. Koeffler HP, Gasson J, Ranyard J, Souza L, Shepard M, Munker R (1987) The recombinant TNFα stimulates production of granulocyte colony-stimulating factor. Blood 70:55–59

    Google Scholar 

  42. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45–53

    Google Scholar 

  43. Krönke M, Hensel G, Schlüter C, Scheurich P, Schütze S, Pfizenmaier K (1988) Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. Cancer Res 48:5417–5421

    Google Scholar 

  44. Lachman LB, Brown DC, Dinarello CA (1987) Growth promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J Immunol 138:2913–2916

    Google Scholar 

  45. Larrick JW, Graham D, Toy K, Lin LS, Senyk G, Findly BM (1987) Recombinant tumor necrosis factor causes activation of human granulocytes. Blood 69:640–644

    Google Scholar 

  46. Laster SM, Wood JG, Gooding LR (1988) Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 141:2629–2634

    Google Scholar 

  47. Le J, Vilcek J (1987) Biology of disease. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest 56:234–248

    Google Scholar 

  48. Maury CPJ, Teppo AM (1987) Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med 166:1132–1137

    Google Scholar 

  49. Meager A, Parti S, Leung H, Peil E, Mahon B (1987) Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 6:305–311

    Google Scholar 

  50. Medcalf RL, Kruithof EKO, Schleuning WD (1988) Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin responsive genes. J Exp Med 168:751–759

    Google Scholar 

  51. Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Möller A, Jacobsen H, Kirchner H (1986) Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 323:816–819

    Google Scholar 

  52. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486

    Google Scholar 

  53. Müller U, Jongeneel CV, Nedospasov SA, Lindahl KF, Steinmetz M (1987) Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex. Nature 325:265–267

    Google Scholar 

  54. Munker R, Koeffler HP (1987) Tumor necrosis factor: recent advances. Klin Wochenschr 65:345–352

    Google Scholar 

  55. Muto Y, Nouri-Aria K, Meager A, Alexander GJM, Eddleston ALW, Williams R (1988) Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet ii:72–74

    Google Scholar 

  56. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555–563

    Google Scholar 

  57. Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, Liggitt D, Patton JS (1987) Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 138:4023–4032

    Google Scholar 

  58. Peters PM, Ortaldo JR, Shalaby RM, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwall BB, Herberman RB, Goeddel DV, Palladino MA (1986) Natural killer-sensitive targets stimulate production of TNF-α but not TNF-β (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol 137:2592–2598

    Google Scholar 

  59. Pfreundschuh MG, Steinmetz HT, Tüschen R, Schenk V, Diehl V, Schaadt M (1989) Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol 25:379–388

    Google Scholar 

  60. Philip R, Epstein LB (1986) Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself,γ-interferon and interleukin-1. Nature 323:86–89

    Google Scholar 

  61. Proietti E, Belardelli F, Di Vito M, Woodrow D, Moss J, Sestili P, Fiers W (1988) Tumor necrosis factorα induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice. Int J Cancer 42:582–591

    Google Scholar 

  62. Raeth U, Schmid H, Hofman J, Wiedenmann B, Kempeni J, Schlick E, Kaufmann M (1989) Intraperitoneal application of recombinant human tumor necrosis factor as an effective palliative treatment of malignant ascites from ovarian and gastroenteropancreatic carcinomas. Proc Am Soc Clin Oncol 8: Abstr. # 703

  63. Ranges GE, Zlotnik A, Espevik T, Dinarello CA, Cerami A, Palladino MA (1988) Tumor necrosis factor α/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med 167:1472–1478

    Google Scholar 

  64. Reem GH, Duggan A, Schleuning M (1989) Immunoregulation and production of tumor necrosis factorα by human thymocytes. Cancer Res 49:3568–3573

    Google Scholar 

  65. Rich EA, Panuska JR, Wallis RS, Wolf CB, Leonard ML, Ellner JJ (1989) Dyscoordinate expression of tumor necrosis factor-alpha by human blood monocytes and alveolar macrophages. Am Rev Resp Dis 139:1010–1015

    Google Scholar 

  66. Robertson PA, Ross HJ, Figlin RA (1989) Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma. Ann Int Med 111:682–684

    Google Scholar 

  67. Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, Old LJ (1986) Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. J Exp Med 164:1350–1355

    Google Scholar 

  68. Sariban E, Imamura K, Luebbers R, Kufe D (1988) Tran scriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest 81:1506–1510

    Google Scholar 

  69. Scheurich P, Ücer U, Krönke, Pfizenmaier K (1986) Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer 38:127–133

    Google Scholar 

  70. Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Peterson E, Slymen DJ, Salmon SE (1986) Raised serum levels of tumour necrosis factor in parasitic infections. Lancet ii: 1364–1365

    Google Scholar 

  71. Schleuning M, Duggan A, Reem GH (1989) Cyclosporine does not inhibit the early transducing signals generated by the activation of human thymocytes. Transpl Proc 20 (Suppl 2):63–68

    Google Scholar 

  72. Schleuning MJ, Dugan A, Reem GH (1989) Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur J Immunol 19:1491–1496

    Google Scholar 

  73. Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factorα. J Exp Med 167:1511–1516

    Google Scholar 

  74. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T (1987) Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 56:803–808

    Google Scholar 

  75. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III, Kufe DW (1988) Recombinant human tumor necrosis factor administered as five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 6:344–350

    Google Scholar 

  76. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL (1986) Genes for the tumor necrosis factorsα andβ are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83:8699–8702

    Google Scholar 

  77. Spriggs D, Imamura K, Rodriguez C, Horiguchi J, Kufe DW (1987) Induction of tumor necrosis factor expression and resistance in a human breast cancer cell line. Proc Natl Acad Sci USA 84:6563–6566

    Google Scholar 

  78. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, Frei E III, Kufe DW (1988) Recombinanthuman tumor necrosis factor administered as 24-h intravenous infusion. A phase I and pharmacologic study. J Natl Canc Inst 80:1039–1044

    Google Scholar 

  79. Starnes HF, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, Brennan MF (1988) Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 82:1321–1325

    Google Scholar 

  80. Stovroff MC, Frakeer DL, Swedenborg JA, Norton JA (1988) Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res 48:4567–4572

    Google Scholar 

  81. Strieter RM, Remick DG, Lynch JP, Spengler RN, Kunkel SL (1989) Interleukin-2-induced tumor necrosis factor-alpha (TNFα) gene expression in human alveolar macrophages and blood monocytes. Am Rev Resp Dis 139:335–342

    Google Scholar 

  82. Sung SSJ, Bjorndahl JM, Wang CY, Kao HT, Fu SM (1988) Production of tumour necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J Exp Med 167:937–953

    Google Scholar 

  83. Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY, Fu SM (1988) Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med 168:1539–1551

    Google Scholar 

  84. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474

    Google Scholar 

  85. Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD, Shires GT (1986) Cachectin/tumor necrosis factor mediates changes of skeletal muscle membrane potential. J Exp Med 164:1368–1373

    Google Scholar 

  86. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A, Lowry SF (1988) Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211–1227

    Google Scholar 

  87. Unglaub R, Maxeiner B, Thoma B, Pfizenmaier K, Scheurich P (1987) Downregulation of tumor necrosis factor sensitivity via modulation of TNF binding capacity by protein kinase C activators. J Exp Med 166:1788–1797

    Google Scholar 

  88. Waage A, Halstensen A, Espevic T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet ii:355–357

    Google Scholar 

  89. Warner SJC, Libby P (1989) Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immun 142:100–109

    Google Scholar 

  90. Warren RS, Donner DB, Starnes HF, Brennan MF (1987) Modulation of endogenous hormone action by recombinant human tumor necrosis factor. Proc Natl Acad Sci USA 84:8619–8622

    Google Scholar 

  91. Wong GHW, Goeddel DV (1986) Tumour necrosis factorsα andβ inhibit virus replication and synergize with interferons. Nature 323:819–822

    Google Scholar 

  92. Wong GHW, Goeddel DV (1988) Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242:941–944

    Google Scholar 

  93. Yokota S, Geppert TD, Lipsky PE (1988) Enhancement of antigenand mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-α. J Immunol 140:531–536

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Universitätsklinikum Großhadern, München

    M. Schleuning & R. Munker

Authors
  1. M. Schleuning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Munker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schleuning, M., Munker, R. Tumor necrosis factor: An update on basic research and clinical applications. Klin Wochenschr 68, 841–846 (1990). https://doi.org/10.1007/BF01662779

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01662779

Key words

Search

Navigation